EBS vs BRKR vs WAT vs SIGA vs A

For growth investors, Waters Corporation (WAT) is the stronger pick with 7.

0% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). Emergent BioSolutions Inc. (EBS) offers the better valuation at 9. 8x trailing P/E (17. 6x forward), making it the more compelling value choice. Analysts rate Emergent BioSolutions Inc. (EBS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Emergent BioSolutions Inc.

(EBS) is the cheapest at 9. 8x versus Waters Corporation at 32. 6x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 35x versus Waters Corporation's 4. 70x — a reasonable growth-adjusted valuation.

Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.

3%, compared to -85. 2% for Emergent BioSolutions Inc. (EBS). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus EBS's -76. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Waters Corporation (WAT) is the lower-risk stock at 1.

07β versus Emergent BioSolutions Inc. 's 1. 83β — meaning EBS is approximately 71% more volatile than WAT relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 109% for Emergent BioSolutions Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.

0% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Emergent BioSolutions Inc. grew EPS 125. 8% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SIGA Technologies, Inc.

(SIGA) is the more profitable company, earning 24. 6% net margin versus -0. 3% for Bruker Corporation — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 6. 9% for BRKR. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 35x versus Waters Corporation's 4. 70x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, SIGA Technologies, Inc. (SIGA) trades at 2. 8x forward P/E versus 24. 4x for Waters Corporation — 21. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for A: 39. 9% to $166. 00.

In this comparison, SIGA (12.

7% yield), A (0. 8% yield), BRKR (0. 3% yield) pay a dividend. EBS, WAT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Emergent BioSolutions Inc. (EBS) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, EBS: -76. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EBS is a small-cap deep-value stock; BRKR is a small-cap quality compounder stock; WAT is a mid-cap quality compounder stock; SIGA is a small-cap deep-value stock; A is a mid-cap quality compounder stock. SIGA, A pay a dividend while EBS, BRKR, WAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.